Cargando…

Is There a Role for [(18)F]FDG PET-CT in Staging MALT Lymphoma?

SIMPLE SUMMARY: MALT lymphoma represents a relatively rare lymphoma subtype that arises in different extranodal anatomic locations. In the current paper we summarize our experience in assessing disease extent and metabolic characteristics of MALT lymphomas with [(18)F]FDG PET-CT at staging, and aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Dan, Perry, Chava, Hazut-Krauthammer, Shir, Kesler, Mikhail, Herishanu, Yair, Luttwak, Efrat, Even-Sapir, Einat, Avivi, Irit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833535/
https://www.ncbi.nlm.nih.gov/pubmed/35159016
http://dx.doi.org/10.3390/cancers14030750
Descripción
Sumario:SIMPLE SUMMARY: MALT lymphoma represents a relatively rare lymphoma subtype that arises in different extranodal anatomic locations. In the current paper we summarize our experience in assessing disease extent and metabolic characteristics of MALT lymphomas with [(18)F]FDG PET-CT at staging, and aim to highlight the strengths and challenges this imaging modality poses. In our data, all extranodal lesions located in subcutaneous-tissue, lung and liver were detected on PET, while some of those located in other tissues (such as along the digestive tract) were not detected on PET. We also evaluated the predictive role of PET in these patients, and found that increased [(18)F]FDG-uptake in extranodal lesions was associated with worse disease progression. ABSTRACT: The role of (18)F-fluorodeoxyglucose ([(18)F]FDG) positron emission tomography—computed tomography (PET-CT) in assessing mucosa-associated lymphoid tissue (MALT) lymphoma is debatable. We retrospectively explored the role of [(18)F]FDG PET-CT in staging and predicting progression-free-survival (PFS) of patients with newly-diagnosed MALT lymphoma. Sixty-six studies were included. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were documented in the “hottest” extranodal and nodal lesions. Extranodal lesions and accompanying nodal disease were detected on PET in 38/66 (57.6%) and 13/66 (19.7%) studies, respectively. Detection rate of extranodal lesions differed significantly between those located in tissues with high/heterogeneous (e.g., stomach) vs low/homogenous (e.g., subcutaneous-tissue, lung) physiologic [(18)F]FDG-uptake (40.4% vs. 100%, p < 0.01). Nodal lesions had significantly lower SUVmax, MTV and TLG compared with extrandodal lesions in the same patients. Detection and [(18)F]FDG-avidity of extranodal lesions were higher in patients with advanced, bulky disease and concomitant marrow/nodal involvement. Increased SUVmax of extranodal lesions predicted shorter PFS (HR 1.10, 95% CI 1.01–1.19, p = 0.02). Higher SUVmax and TLG showed trends towards shorter PFS in patients with localized disease. In conclusion, detection rate of extranodal MALT lymphoma lesions located in tissues with low/homogeneous physiologic [(18)F]FDG-uptake is excellent on [(18)F]FDG PET-CT. When detected, SUVmax of extranodal lesions may predict PFS.